Generated by AI
Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems. The company’s core LungFit platform generates nitric oxide from ambient air and delivers it in a controlled way for respiratory care, with applications centered on neonatal respiratory conditions and other serious lung diseases. Beyond Air also operates development programs aimed at extending its nitric oxide technology across additional respiratory, neurological, and oncology-related uses. Its business is organized around Beyond Air, Beyond Cancer, and NeuroNos, reflecting a broader platform approach that combines device engineering with therapeutic development. Headquartered in Garden City, New York, Beyond Air serves the healthcare market through products and programs designed for hospital-based clinical use and specialized medical treatment settings.
Website900 Stewart Avenue
Garden City, NY, 11530
United States
The latest articles about XAIR.
Beyond Air Inc (XAIR) posted record quarterly revenue of $2.3 million and positive gross margin while awaiting FDA approval of its second-generation LungFit PH system.
Summary of Sep 1's posts. Generated by AI.
Summary of Aug 31's posts. Generated by AI.
Summary of Aug 31's posts. Generated by AI.
Investors talking about XAIR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.